Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Your white blood cells could help cure cancer – Here's how to donate

NCT ID NCT02821806

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 18, 2026 · Updated 5 times

Summary

This study collects white blood cells from healthy volunteers to help researchers develop new immune-based cancer treatments. Participants undergo a 4-6 hour procedure called leukapheresis, where a machine separates white cells from the rest of the blood. Donors must be 18 or older, meet health criteria, and can donate every 21 days. The cells are used in the lab to improve T-cell therapies that may one day fight tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help scientists develop better T-cell therapies that use a patient's own immune system to fight cancer.
What could go wrong
This is a sample-collection study, not a treatment trial. The cells are used for lab research, so there is no direct benefit to participants or guarantee that new therapies will result.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2016

Expected to finish

Feb 2035

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants are healthy volunteers, selected from the general population. Employees may also volunteer per the protocol.@@@

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: * Age greater than or equal to 18 years old and able to give consent. * Adequate clinical parameters (all of the following): * Afebrile (temperature less than or equal to 37.5 degree C) * Systolic blood pressure less than or equal to180 mmHg * Diastolic blood pressure less than or equal to100 mmHg * Weight greater than or equal to 110 lbs. * Heart rate between 50-100 beats/minute * Adequate bilateral antecubital venous access for a 2 arm apheresis procedure * Females of child-bearing potential should not be pregnant or breast-feeding. * Within 30 days of pheresis donation, donors must be negative for infectious disease work-up: Antibody screen for Hepatitis B, Hepatitis C; HIV, HTLV-I/II, T. cruzi (Chagas agent), West Nile, and syphilis (RPR) * Within 30 days of pheresis donation, donor must have: * Hemoglobin: * Women greater than or equal to 12.5 gm/dL * Men greater than or equal to 13.0 gm/dL * Platelets greater than or equal to 100,000/microliter * Total WBC greater than or equal to 2 K/microliter EXCLUSION CRITERIA: * History of medical illness that in the estimation of the PI or DTM physician precludes donation of PBMCs. * Current psychiatric diagnosis that would compromise compliance with donation or precludes appropriate informed consent. * Presence of any blood transmissible infectious disease that cannot be cleared prior to PBMC donation and poses an unacceptable risk for the recipient. * Active malignancy will exclude the donor. Any history of malignancy will be considered on a case by case basis in accordance with NIH/DTM criteria. * If the participant answers Yes to any initial screening question, the participant will be considered ineligible. * If the participant is deferred according to DTM Cellular Therapy Screening Standard Operating Procedures (SOP), the participant will be considered ineligible.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.